BioSeek licenses peptides from Amylin

BioSeek, a USA-based pioneer in the application of predictive human biology to drug discovery, has exclusively licensed two novel anti-inflammatory peptides from Amylin Pharmaceuticals. The two novel peptides were identified as candidates for development by BioSeek as a result of an ongoing joint research collaboration initiated between the two companies in 2007. These two peptides will be the basis for proprietary optimization and development programs at BioSeek for potential indications outside of Amylin's core therapeutic focus.

Under the collaboration, BioSeek applied its BioMAP human biology screening systems to evaluate the potential of 500 peptides in Amylin's proprietary polypeptide hormone library, PHORMOL, to treat a range of inflammatory conditions. From that pool, BioSeek was granted the right to select and license two of the peptides for its own preclinical portfolio. In exchange for milestones and royalties payable to Amylin, BioSeek has the right to optimize, develop and out-license the two selected peptides. It is also eligible to receive royalties if Amylin develops or licenses an additional limited set of peptides for uses identified in the collaboration. Further financial terms were not disclosed.